- Home
- REFI vs PRQR Comparison
REFI vs PRQR Comparison
Compare REFI & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- PRQR
- Stock Information
- Founded
- REFI 2021
- PRQR 2012
- Country
- REFI United States
- PRQR Netherlands
- Employees
- REFI N/A
- PRQR N/A
- Industry
- REFI Real Estate Investment Trusts
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- REFI Real Estate
- PRQR Health Care
- Exchange
- REFI Nasdaq
- PRQR Nasdaq
- Market Cap
- REFI 274.3M
- PRQR 232.8M
- IPO Year
- REFI 2021
- PRQR 2014
- Fundamental
- Price
- REFI $13.45
- PRQR $2.15
- Analyst Decision
- REFI Strong Buy
- PRQR Strong Buy
- Analyst Count
- REFI 3
- PRQR 8
- Target Price
- REFI $20.00
- PRQR $8.88
- AVG Volume (30 Days)
- REFI 129.1K
- PRQR 368.1K
- Earning Date
- REFI 11-06-2025
- PRQR 11-06-2025
- Dividend Yield
- REFI 15.24%
- PRQR N/A
- EPS Growth
- REFI N/A
- PRQR N/A
- EPS
- REFI 1.84
- PRQR N/A
- Revenue
- REFI $56,608,781.00
- PRQR $20,129,184.00
- Revenue This Year
- REFI $9.93
- PRQR N/A
- Revenue Next Year
- REFI $4.99
- PRQR N/A
- P/E Ratio
- REFI $7.36
- PRQR N/A
- Revenue Growth
- REFI 2.58
- PRQR 8.65
- 52 Week Low
- REFI $12.76
- PRQR $1.07
- 52 Week High
- REFI $16.29
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- REFI 42.08
- PRQR 48.54
- Support Level
- REFI $13.08
- PRQR $1.91
- Resistance Level
- REFI $13.68
- PRQR $2.50
- Average True Range (ATR)
- REFI 0.32
- PRQR 0.16
- MACD
- REFI -0.08
- PRQR -0.03
- Stochastic Oscillator
- REFI 25.15
- PRQR 41.44
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.